Terapevticheskii arkhivTerapevticheskii arkhivТерапевтический архив0040-36602309-5342LLC Obyedinennaya Redaktsiya10483410.26442/00403660.2022.01.201324ReviewsОбзорыReview ArticlePrimary hyperaldosteronism: indications for screeningПервичный гиперальдостеронизм: показания для скринингаhttps://orcid.org/0000-0002-8826-9690ChikhladzeNovella M.ЧихладзеНовелла Михайловна
Russian Federation

д-р мед. наук, проф., вед. науч. сотр.

novella.cardio@mail.ruNational Medical Research Center of CardiologyФГБУ «Национальный медицинский исследовательский центр кардиологии» Минздрава России150120229411071131403202214032022Copyright ©; 2022, Consilium MedicumCopyright ©; 2022, ООО "Консилиум Медикум"2022Consilium MedicumООО "Консилиум Медикум"https://creativecommons.org/licenses/by-nc-sa/4.0https://ter-arkhiv.ru/0040-3660/article/view/104834

The review discusses the current state of the problem of screening patients for early detection of primary hyperaldosteronism (PHA) as a potential cause of arterial hypertension (AH). The features of screening, methodological errors that make it difficult to interpret the results of the study are considered. The screening criteria are analyzed, based on which it is possible to assess the probability of diagnosis of PHA and judge its prevalence in various populations of patients with AH – categories of high risk for the development of PHA. Attention is drawn to the low level of screening in patients with AH in order to detect PHA , and to the need for wider familiarization of doctors with the methods of screening and diagnosis of PHA as the cause of uncontrolled AH. The importance of timely diagnosis of PHA and its targeted treatment to reduce the risk of cardiovascular complications associated with hypersecretion of aldosterone is emphasized.

В обзоре обсуждается современное состояние проблемы скринингового обследования пациентов с целью раннего выявления первичного гиперальдостеронизма (ПГА) как потенциальной причины артериальной гипертонии (АГ). Рассмотрены особенности проведения скрининга, методические ошибки, затрудняющие интерпретацию результатов исследования. Проанализированы критерии скрининга, на основании которых можно оценить вероятность диагностики ПГА и судить о его распространенности в различных популяциях больных АГ – категориях высокого риска развития ПГА. Обращено внимание на низкий уровень скрининга больных АГ с целью выявления ПГА, на необходимость более широкого ознакомления врачей с методами скрининга и диагностики ПГА как причины неконтролируемого течения АГ. Подчеркивается важность своевременной диагностики ПГА и его целенаправленного лечения для снижения риска сердечно- сосудистых осложнений, связанных с гиперсекрецией альдостерона.

primary hyperaldosteronismscreeningarteral hypertensionпервичный гиперальдостеронизмскринингартериальная гипертонияConn JW. Presidential address. I. Painting background. II. Primary aldosteronism, a new clinical syndrome. J Lab Clin Med. 1955;45:3-17.Conn JW, Knopf RF, Nesbit RM. Clinical characteristics of primary aldosteronism from an analysis of 145 cases. Am J Surg. 1964;107:159-72. DOI:10.1016/0002-9610(64)90252-1Ferriss JB, Beevers DG, Brown JJ, et al. Clinical, biochemical and pathological features of low-renin ("primary") hyperaldosteronism. Am Heart J. 1978;95(3):375-88. DOI:10.1016/0002-8703(78)90370-8Young WF. Primary aldosteronism: renaissance of a syndrome. Clin Endocrinol (Oxf). 2007;66(5):607-18. DOI:10.1111/j.1365-2265.2007.02775.xFunder JW, Carey RM, Mantero F, et al. The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2016;101(5):1889-916. DOI:10.1210/jc.2015-4061Rossi GP, Bisogni V, Bacca AV, et al. The 2020 Italian Society of Arterial Hypertension (SIIA) practical guidelines for the management of primary aldosteronism. Int J Cardiol Hypertens. 2020;5. DOI:10.1016/j.ijchy.2020.100029Mulatero P, Stowasser M, Loh KC, et al. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab. 2004;89:1045-50. DOI:10.1210/jc.2003-031337Meng Z, Zhou L, Dai Z, et al. The Quality of Clinical Practice Guidelines and Consensuses on the Management of Primary Aldosteronism: A Critical Appraisal. Front Med (Lausanne). 2020;7:136. DOI:10.3389/fmed.2020.00136Milliez P, Girerd X, Plouin PF, et al. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol. 2005;45(8):1243-8. DOI:10.1016/j.jacc.2005.01.015Monticone S, Burrello J, Tizzani D, et al. Prevalence and Clinical Manifestations of Primary Aldosteronism Encountered in Primary Care Practice. J Am Coll Cardiol. 2017;69(14):1811-20. DOI:10.1016/j.jacc.2017.01.052Nishikawa T, Omura M, Satoh F, et al. Guidelines for the diagnosis and treatment of primary aldosteronism – the Japan Endocrine Society 2009. Endocr J. 2011;58(9):711-21. DOI:10.1507/endocrj.ej11-01331Baguet JP, Steichen O, Mounier-Véhier C, Gosse P. SFE/SFHTA/AFCE consensus on primary aldosteronism, part 1: Epidemiology of PA, who should be screened for sporadic PA? Ann Endocrinol (Paris). 2016;77(3):187-91. DOI:10.1016/j.ando.2016.01.006Amar L, Plouin PF, Steichen O. Aldosterone-producing adenoma and other surgically correctable forms of primary aldosteronism. Orphanet J Rare Dis. 2010;5:9. DOI:10.1186/1750-1172-5-9Шхвацабая И.К., Чихладзе Н.М. Гиперальдостеронизм и артериальная гипертония. М.: Медицина, 1984 [Shkhvatsabaia IK, Chihladze NM. Giperal'dosteronizm i arterial'naia gipertoniia. Moscow: Meditsina, 1984 (in Russian)].Mosso L, Carvajal C, González A, et al. Primary aldosteronism and hypertensive disease. Hypertension. 2003;42(2):161-5. DOI:10.1161/01.HYP.0000079505.25750.11Williams JS, Williams GH, Raji A, et al. Prevalence of primary hyperaldosteronism in mild to moderate hypertension without hypokalaemia. J Hum Hypertens. 2006;20(2):129-36. DOI:10.1038/sj.jhh.1001948Kaplan NM. Is there an unrecognized epidemic of primary aldosteronism? Con Hypertension. 2007;50(3):454-8. DOI:10.1161/HYPERTENSIONAHA.106.086124Käyser SC, Dekkers T, Groenewoud HJ, et al. Study heterogeneity and estimation of prevalence of primary aldosteronism: a systematic review and meta-regression analysis. J Clin Endocrinol Metab. 2016;101(7):2826-35. DOI:10.1210/jc.2016-1472Schmiemann G, Gebhardt K, Hummers-Pradier E, et al. Prevalence of hyperaldosteronism in primary care patients with resistant hypertension. J Am Board Fam Med. 2012;25:98-103. DOI:10.3122/jabfm.2012.01.110099Ruhle BC, White MG, Alsafran S, et al. Keeping primary aldosteronism in mind: Deficiencies in screening at-risk hypertensives. Surgery. 2019;165(1):221-7. DOI:10.1016/j.surg.2018.05.085Olivieri O, Ciacciarelli A, Signorelli D, et al. Aldosterone to Renin ratio in a primary care setting: the Bussolengo study. J Clin Endocrinol Metab. 2004;89(9):4221-6. DOI:10.1210/jc.2003-032179Rossi GP, Bernini G, Caliumi C, et al. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol. 2006;48(11):2293-300. DOI:10.1016/j.jacc.2006.07.059Calhoun DA. Is there an unrecognized epidemic of primary aldosteronism? Pro. Hypertension. 2007;50(3):447-53. DOI:10.1161/HYPERTENSIONAHA.106.086116Douma S, Petidis K, Doumas M, et al. Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study [published correction appears in Lancet. 2008;372(9655):2022]. Lancet. 2008;371(9628):1921-6. DOI:10.1016/S0140-6736(08)60834-XEgidi G, Schmiemann G, Gebhardt K. Is aldosteronism really a relatively common cause of hypertension? CMAJ. 2018;190(13):E403. DOI:10.1503/cmaj.68999Käyser SC, Deinum J, de Grauw WJ, et al. Prevalence of primary aldosteronism in primary care: a cross-sectional study. Br J Gen Pract. 2018;68(667):e114-22. DOI:10.3399/bjgp18X694589Kaplan NM. Current diagnosis and treatment of primary aldosteronism. Expert Rev Cardiovasc Ther. 2010;8(11):1527-30. DOI:10.1586/erc.10.135Wu VC, Hu YH, Er LK, et al. Case detection and diagnosis of primary aldosteronism – The consensus of Taiwan Society of Aldosteronism. J Formos Med Assoc. 2017;116(12):993-1005. DOI:10.1016/j.jfma.2017.06.004Sang X, Jiang Y, Wang W, et al. Prevalence of and risk factors for primary aldosteronismamong patients with resistant hypertension in China. J Hypertens. 2013;31(7):1465-72. DOI:10.1097/HJH.0b013e328360ddf6Ратнер Н.А. Артериальные гипертонии. М.: Медицина, 1974 [Ratner NA. Arterial'nye gipertonii. Moscow: Meditsina, 1974 (in Russian)].Kim SH, Ahn JH, Hong HC, et al. Changes in the clinical manifestations of primary aldosteronism. Korean J Intern Med. 2014;29(2):217-25. DOI:10.3904/kjim.2014.29.2.217Lee JM, Kim MK, Ko SH, et al. Clinical guidelines for the management of adrenal incidentaloma. Endocrinol Metab (Seoul). 2017;32(2):200-18. DOI:10.3803/EnM.2017.32.2.200Бельцевич Д.Г., Мельниченко Г.А., Кузнецов Н.С., и др. Клинические рекомендации Российской ассоциации эндокринологов по дифференциальной диагностике инциденталом надпочечников. Эндокринная хирургия. 2016;10(4):31-42 [Beltsevich DG, Melnichenko GA, Kuznetsov NS, et al. Russian Association of Endocrinologists clinical practice guideline for adrenal incidentalomas differential diagnosis. Endocrine Surgery. 2016;10(4):31-42 (in Russian)]. DOI:10.14341/serg2016431-42Fassnacht M, Arlt W, Bancos I, et al. Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol. 2016;175(2):G1-34. DOI:10.1530/EJE-16-0467Stowasser M, Bachmann AW, Huggard PR, et al. Severity of hypertension in familial hyperaldosteronism type I: relationship to gender and degree of biochemical disturbance. J Clin Endocrinol Metab. 2000;85(6):2160-6. DOI:10.1210/jcem.85.6.6651Чихладзе Н.М., Фаворова О.О., Чазова И.Е. Семейная форма гиперальдостеронизма I типа: клиническое наблюдение и обзор литературы. Терапевтический архив. 2018;90(9):115-22 [Chikladze NM, Favorova OO, Chazova IE. Family hyperaldosteronism type I: a clinical case and review of literature. Terapevticheskii Arkhiv (Ter. Arkh.). 2018;90(9):115-22 (in Russian)]. DOI:10.26442/terarkh2018909115-122Gonzaga CC, Gaddam KK, Ahmed MI, et al. Severity of obstructive sleep apnea is related to aldosterone status in subjects with resistant hypertension. J Clin Sleep Med. 2010;6(4):363-8.Umpierrez GE, Cantey P, Smiley D, et al. Primary aldosteronism in diabetic subjects with resistant hypertension. Diabetes Care. 2007;30(7):1699-703. DOI:10.2337/dc07-0031Mulatero P, Monticone S, Burrello J, et al. Guidelines for primary aldosteronism: uptake by primary care physicians in Europe. J Hypertens. 2016;34(11):2253-7. DOI:10.1097/HJH.0000000000001088